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Morphine, fentanyl, and oxycodone are widely used as analgesics, and recently hydromorphone has been
approved in Japan. Although all of these are selective for m-opioid receptors (MORs) and have similar
structures, their analgesic potencies and adverse effects (AEs) are diverse. Recent molecular analyses of
MOR signaling revealed that the G protein-mediated signaling pathway causes analgesic effects and the
b-arrestin-mediated signaling pathway is responsible for AEs. We used several cell-based analyses that
selectively measure cellular responses activated by either G protein- or b-arrestin-mediated pathways.
GloSensor™ cAMP, CellKey™, and receptor internalization assays were performed with four different
types of cells stably expressing differentially labelled MOR. EC50 values measured by cAMP and CellKey™
assays had potencies in the order fentanyl  hydromorphone < morphine  oxycodone, all also
exhibiting full agonist responses. However, in the internalization assay, only fentanyl elicited a full
agonist response. Hydromorphone had the strongest potency next to fentanyl; however, contribution of
the b-arrestin-mediated pathway was small, suggesting that its effect could be biased toward the G
protein-mediated pathway. Based on these properties, hydromorphone could be chosen as an effective
analgesic.
© 2019 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).physiology, National Cancer
yo 104-0045, Japan. Fax: þ81
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).1. Introduction
For acute or chronic cancer pain, strong opioids such as
morphine have been used as the last treatment choice in the WHO
3-step analgesic ladder.1 However, opioids often cause adverse ef-
fects (AEs) and lead to economic burden2 so that pharmacological
proﬁles must be well understood3 to efﬁciently use them.nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
S. Manabe et al. / Journal of Pharmacological Sciences 140 (2019) 171e177172Opioids bind to opioid receptors (ORs, classiﬁed as m, d, or k) that
belong to the G protein-coupled receptors (GPCRs).4 Among them,
m-opioid receptors (MORs) play important roles in mechanisms of
pain and the elucidation of AEs.3 Different signaling cascades are
responsible for different responses to MOR, which have allowed us
to separate analgesic from AE signaling.5e7 Such diverse effects are
attributed to diverse cellular signaling including inhibition of
adenylate cyclase to cause a variety of pharmacological effects.3,4,8
Opioid-induced AEs include intolerance, toxicity, and depen-
dence. With such AE, pain management is not always easy and
requires a steep increase in analgesic dosage over time.2,9 To avoid
this, a change to non-opioid or other opioid analgesics (opioid
switching) is required in clinical situations. Following the concept
of “biased agonism”, some agonists differentially activate signaling
molecules downstream of GPCRs; based on which pathways these
agonists activate, use of one opioid analgesic over the other could
result in better clinical responses and represents novel strategies in
pain management.4,10 Recent molecular analyses of the properties
of MOR revealed two downstream pathways: one leading tomainly
analgesic effects through a G protein-mediated and another
through the b-arrestin-mediated pathway to cause unpleasant AEs
such as respiratory depression.3,11,12 To further understand the
mechanism, many experimental approaches have been used.13
Among opioids, morphine (MRP), oxycodone (OXY), and fentanyl
(FEN) are widely used to alleviate moderate to severe pain, espe-
cially for cancer patients.14 and in 2017 hydromorphone (HDM)was
approved as another strong opioid in Japan.15
HDM, a semi-synthetic morphine derivative ﬁrst synthesized in
1924, differs only at its benzol ring having a keto-group instead of a
hydroxy group and only one functional group is different between
HDM and OXY (Fig. 1). As of now, HDM has been employed in 45
countries and regions alongside standard opioids.14,16,17 Despite
this, the properties of HDM, particularly its effects on ORs are
poorly clariﬁed. In in vitro studies of cells overexpressing opioid m, d,
and k receptors, only three reports are available to compare the
effects of HDM with other opioids.18e20 We therefore proposed to
compare the properties and potency of HDM with other opioids
using in vitro receptor assay systems, especially focusing on the
biased signal mechanisms.3,102. Materials and methods
2.1. Chemicals
The following reagents were used: D-Ala(2)-N-Me-Phe(4)-Gly-
ol(5)-enkephalin (DAMGO), forskolin, 3-isobutyl-1-
methylxanthine (IBMX), Ro 20e1724 (SigmaeAldrich, St. Louis,
MO, USA); HaloTag® pH Sensor Ligand (Promega, Madison, WI,A
Morphine (MRP)
B
Oxycodone (OXY)
C
Hydr
Fig. 1. Molecular structures oUSA); Hoechst 33342 (Dojinkagaku, Kumamoto, Japan); morphine
hydrochloride (Takeda Pharmaceutical Co., Ltd., Tokyo, Japan);
fentanyl (Janssen Pharmaceutical K. K., Tokyo, Japan); oxycodone
hydrochloride hydrate (Shionogi & Co., Ltd., Osaka, Japan); and
hydromorphone hydrochloride (Daiichi Sankyo Co., Ltd., Tokyo,
Japan). Forskolin, IBMX, and Ro 20e1724 were diluted with
dimethyl sulfoxide (DMSO) and other chemicals were diluted
with water.
2.2. Construction of plasmids and generation of stable cell lines
Human MOR (hMOR) cDNA (NM_000914) with/without a stop
codon was ampliﬁed from a Flexi ORF clone (Promega). The
ampliﬁed hMOR fragment, N-terminal HaloTag® (Kazusa DNA
Research Institute, Chiba, Japan) or Flag-fused hMOR were intro-
duced into a pcDNA3.1 (þ) vector (Life Technologies, Carlsbad, CA,
USA). Additionally, a GFP coding sequence was inserted into the 3'
terminus of the stop codon-deleted hMOR sequence. Human
embryonic kidney 293 cells (HEK293, American Type Culture
Collection, Manassas, VA, USA) stably expressing HaloTag® fused
MOR (Halotag-MOR), Flag-fused MOR (Flag-MOR), or GFP fused
MOR (GFP-MOR) were generated through transfection of plasmids
using Lipofectamine (Life Technologies), and selected based on
MOR activity measured using the CellKey™ assay. pGloSensor™
22F plasmid (Promega) was transfected into hMOR-positive cells
to generate a stable hMOR and pGloSensor™ 22F (MOR/pGS22F)
expressing cell line.
2.3. Cell culture
HEK293 cells (stably expressing Flag-, Halotag-, GFP-MOR or
MOR/pGS22F) were cultured in Dulbecco's modiﬁed Eagle's
medium (DMEM) supplemented with 10% fetal bovine serum, 1%
penicillin/streptomycin, and 700 mg/mL G418 disulfate aqueous
solution (Gibco, Palo Alto, CA, USA) to Flag-MOR and GFP-MOR,
or 5 mg/mL puromycin (InvivoGen, San Diego, CA, USA) to
Halotag-MOR in a humidiﬁed atmosphere containing 5% CO2 at
37 C.
2.4. cAMP assay with GloSensor™
The GloSensor™ cAMP assay was performed according to
Meguro et al.21 Brieﬂy, MOR/pGS22F cells were plated at
3.0  104 cells/well in poly-D-lysine-coated 96-well clear-
bottomed plates (Corning, Corning, NY, USA). The next day,
cells were equilibrated with diluted GloSensor™ reagent
(Promega) at RT for 2 h, and luminescence intensity was
measured every 2.5 min for 40 min in the Synergy™ H1 (BioTekomorphone (HDM)
D
Fentanyl (FEN)
f each opioid analgesic.
Fig. 2. Changes in cAMP levels induced by several opioids in HEK293 cells co-
expressing m-opioid receptor (MOR)/pGS22F. Intracellular cAMP levels in cells
treated with various concentrations of morphine (MRP), oxycodone (OXY), hydro-
morphone (HDM), or fentanyl (FEN) were measured with the GloSensor™ cAMP assay.
Concentration-response curves of the four opioids (MRP, OXY, HDM, and FEN) were
described by calculating intracellular cAMP levels relative to data obtained at 105 M
MRP. All data are presented as means ± S.E.M. for 3 independent experiments
(n ¼ 6e12).
S. Manabe et al. / Journal of Pharmacological Sciences 140 (2019) 171e177 173Instruments Inc., Winooski, VT, USA). Drugs were added and the
luminescence intensity at the 10-min endpoint was deﬁned as
the baseline. Forskolin (3  106 M) was added at 10 min.
DLuminescence intensity was calculated as the intensity of each
point subtracted from baseline, and the area under the time-
Dluminescence intensity curve (AUC) was deﬁned as the intra-
cellular cAMP level (see Suppl. Fig. 2). AUC of each sample was
subtracted from that of the negative control sample (Forskolin
(3  106 M) alone). MOR responses were presented as per-
centage intracellular cAMP inhibition calculated by dividing the
corrected AUC by data of standard sample (105 M MRP).
2.5. CellKey™ assay
The CellKey™ assay has been described previously.21,22
Brieﬂy, cells were seeded at densities of 7.0  104 (Flag-MOR,
Halotag-MOR), 5.0  104 (GFP-MOR), 3.0  104 cells/well (MOR/
pGS22F) in CellKey™ poly-D-Lysine (Sigma Aldrich) coated 96-
well microplates with an embedded electrode at the bottom of
each well, and then incubated for 24 h.21,22 CellKey™ buffer
composed of Hank's balanced salt solution (in mM: 1.3 CaCl2・
2H2O, 0.81 MgSO4, 5.4 KCl, 0.44 KH2PO4, 4.2 NaHCO3, 136.9
NaCl, 0.34 Na2HPO4, and 5.6 D-glucose) containing 20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and 0.1%
bovine serum albumin (BSA) was used. Cells were incubated for
30 min at 28 C before assays. Changes in the impedance of an
induced extracellular current (dZiec) in each well were
measured every 10s for up to 30 min; taking the ﬁrst 5 min as
baseline, before drug treatment and dZiec measurement for
25 min. Magnitude of changes in dZiec values were deﬁned as
DZiec (Suppl. Fig. 1). DZiec values for each sample were cor-
rected by that of the negative control sample. The standard
sample was DZiec by MRP reached peak at the minimum con-
centrations as indicated.
2.6. Receptor internalization assay with GFP-MOR
Cells expressing GFP-MOR were plated at 6.0  104 cells/well
in 8-well chambered coverglasses (Thermo Fisher Scientiﬁc,
Waltham, MA, USA) coated with polyethyleneimine, and then
incubated for 24 h. Cells were washed with the internalization
buffer (in mM; 10 HEPES, 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2 and
10 D-glucose at pH7.4) and stained with 4 mg/mL Hoechst 33342
for 10 min at 37 C. Cells were then treated with opioid agonists
or DAMGO and changes in localization of GFP-MOR and cell
densities were captured by confocal microscopy (FLUOVIEW
FV10i, OLYMPUS, Tokyo, Japan) every 30 min up to 180 min.
2.7. Internalization assay with Halotag-MOR
Internalization assay was performed with Halotag-MOR. Cells
were stained with Hoechst 33342 for 15 min followed the pH
sensor ligand at 0.5  106 M for 30 min (5% CO2 at 37 C) and
washed once with the internalization buffer. Red spots in the
cells were recorded by FLUOVIEW FV10i and counted using
MetaMorph® 7.7 (Molecular Devices, San Jose, CA, USA). The
density of “Spot count/cell” for each well before drug applica-
tion was calculated and deﬁned as 100% and data obtained every
30 min after opioid treatment. Graphs were made using
GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA).
2.8. Statistical analysis and principles
Data are presented as means with S.E.M. for at least 3 inde-
pendent experiments. Statistical analysis was performed using atwo-way analysis of variance (ANOVA) followed by the
TukeyeKramer test (GraphPad Prism 7). P < 0.05 was considered
statistically signiﬁcant.
All experiments were approved and performed in accordance
with the Guide for Genetic Modiﬁcation Safety Committee, Na-
tional Cancer Center, Japan.
3. Results
3.1. Effects of each opioid agonist on intracellular cAMP levels
measured with the GloSensor™ cAMP assay
We ﬁrst measured intracellular cAMP levels as a result of acti-
vation of the G protein-mediated pathway using HEK293 cells
expressing MOR/pGS22F.23 We chose MRP, OXY, HDM and FEN as
clinically used opioids (Fig. 1). All opioids caused a concentration-
dependent decrease in cAMP levels (Fig. 2 and see Suppl. Fig. 1
for MRP and HDM). EC50 values were the highest in FEN followed
by HDM (FEN  HDM < MRP  OXY; Fig. 2 and Table 1) and some
differences were clear between HDM and both OXY and MRP. In
addition, there were signiﬁcant differences in Emax values between
HDM and both OXY and FEN (Fig. 2).
3.2. The potency and efﬁcacy of each opioid agonist measured using
CellKey™
We then used the CellKey™ system to measure whole cell MOR
activity21,22 using four types of cells stably expressing each of Flag-
MOR, GFP-MOR, Halotag-MOR or co-expressing MOR/pGS22F. All
opioids elicited increases in cellular impedance in a concentration-
dependentmanner (Fig. 3: (A) Flag-MOR, (B) MOR/pGS22F, (C) GFP-
MOR and (D) Halotag-MOR; and Suppl. Fig. 2: MRP and HDM). EC50
values were FEN  HDM < MRP < OXY in all four cell types (Fig. 3
and Table 2). HDMwas the second most potent agonist after FEN in
terms of EC50 values and showed different EC50 compared to both
OXYand MRP (Fig. 3 and Table 2). Although each opioid behaved as
an almost full-agonist in the MOR assay, Emax was signiﬁcantly
different between HDM and other opioids, speciﬁcally OXYand FEN
(Flag-MOR) and OXY and FEN (MOR-pGS22F), with no difference
among four opioids in GFP-MOR or with FEN alone (Halotag-MOR)
(Fig. 2 and Table 2). Although there were slight differences in EC50
depending on the opioid, HDMwas the second most potent agonist
(Figs. 2 and 3 and Tables 1 and 2).
Table 1
Emax and EC50 of each opioid with the GloSensor™ cAMP assay.
Log EC50 (M) Emax (%)
HDM 7.60 ± 0.29 97.67 ± 9.40
OXY 6.17 ± 0.22**** 133.40 ± 14.71**
FEN 7.99 ± 0.28n.s. 143.40 ± 11.86***
MRP 6.68 ± 0.24** 100.00 ± 9.15n.s.
Emax (means ± S.E.M.) and log EC50 (means ± S.E.M.) were calculated according to
the results of Fig. 2.
**p < 0.01,***p < 0.001, and ****p < 0.0001 versus HDM. n.s., not signiﬁcant.
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expressing GFP-MOR
Internalization is a process thought to be activated by the b-
arrestin-mediated signaling pathway.3 To measure MOR internali-
zation from cell surface to cytosol, cells stably expressing GFP-MOR
were evaluated. GFP-MOR was localized at the cell surface before
stimulation (Fig. 4). After treating the cells for 30 min, all opioid-
treated cells showed internalization of GFP-MOR, whereas
vehicle-treated cells did not (Fig. 4). Particularly, FEN and DAMGO
elicited robust MOR internalization within 30 min, which persistedFig. 3. Effects of several opioid analgesics on m-opioid receptor (MOR) activity measured
Potencies of each agonist [morphine (MRP), oxycodone (OXY), hydromorphone (HDM), or fe
concentrations of opioids at the indicated concentrations. Concentration-response curves of
(A-C) and 106 M (D) MRP. The four types of MOR-expressing HEK293 cells were: Flag-tagge
(D). All points are presented as means ± S.E.M. for 3 or 4 independent experiments (n ¼ 6
Table 2
Emax and EC50 of each opioid with the CellKey™ assay in four cells types.
Flag-MOR MOR/pGS22F
Log EC50 (M) Emax (%) Log EC50 (M) Emax (%)
HDM 7.76 ± 0.14 82.2 ± 3.38 7.69 ± 0.08 95.8 ± 2.63
OXY 5.90 ± 0.09**** 125.4 ± 7.17**** 5.89 ± 0.08**** 157.1 ± 7.46***
FEN 7.82 ± 0.12n.s. 137.9 ± 5.23**** 8.05 ± 0.10n.s. 169.2 ± 6.46***
MRP 6.60 ± 0.11**** 100.0 ± 4.73n.s. 6.82 ± 0.15** 100.0 ± 6.26n.s
Emax (means ± S.E.M.) and log EC50 (means ± S.E.M.) were calculated according to the re
**p < 0.01,***p < 0.001, and ****p < 0.0001 versus HDM. n.s., not signiﬁcant.until 60 min and after 180 min, internalized MOR seemed to be
concentrated and formed large pits. MRP, OXY, and HDM caused
less internalization of GFP-MOR compared to FEN and DAMGO
(Fig. 4).3.4. Internalization of MORs by each opioid in cells stably
expressing Halotag-MOR
Although there was a certain tendency that some opioids
caused receptor internalization with the cells expressing GFP-
MOR as shown in Fig. 4, qualiﬁcation by counting receptor
numbers seemed to be subjective. Alternatively, we used cells
stably expressing Halotag-MOR previously stained the HaloTag®
with pH sensor ligand to quantify the internalization induced by
each opioid. Halotag-MOR bound to the pH sensor ligand shifts
from non-ﬂuorescent to red in local acidic conditions, manifesting
as red spots24 (Suppl. Fig. 3). Upon application, FEN and DAMGO
induced the signiﬁcant appearance of red spots, possibly localized
to the endoplasmic reticulum where pH is low. The increases in
numbers of FEN- and DAMGO-induced red spots were time-
dependent until 150 min (Fig. 5B). With OXY, MRP and HDM,
there was also a time-dependent accumulation of red spots inby the CellKey™ system in four types of cells expressing differentially tagged MORs.
ntanyl (FEN)] were measured by the CellKey™ system. Cells were treated with various
the four opioids were described by calculating DZiec relative to data obtained at 105 M
d MOR (A), MOR co-expressed with pGS22F (B), GFP-tagged MOR (C), and Halotag-MOR
e14).
GFP-MOR Halotag-MOR
Log EC50 (M) Emax (%) Log EC50 (M) Emax (%)
7.98 ± 0.10 95.4 ± 2.98 8.32 ± 0.13 95.7 ± 3.50
* 6.36 ± 0.14**** 111.4 ± 7.71n.s. 6.54 ± 0.15**** 114.6 ± 7.40n.s.
* 8.38 ± 0.14n.s. 117.6 ± 5.69n.s. 8.59 ± 0.14n.s. 135.4 ± 5.69***
. 7.17 ± 0.08** 100.0 ± 2.98n.s. 7.31 ± 0.16*** 100.0 ± 5.75n.s.
sults of Fig. 3.
Fig. 4. Internalization of m-opioid receptors (MORs) induced by several opioids in HEK293 cells expressing GFP-MOR. Internalization of GFP-tagged MOR was detected by confocal
microscopy in HEK293 cells stably expressing GFP-MOR at four time points: 0, 30, 60, and 180 min, after treatment with morphine (MRP), oxycodone (OXY), hydromorphone
(HDM), or fentanyl (FEN) or D-Ala(2)-N-Me-Phe(4)-Gly-ol(5)-enkephalin (DAMGO) at the indicated concentrations. Arrow heads indicate ﬂocculated MOR in the cells. Scale
bar ¼ 20 mm.
S. Manabe et al. / Journal of Pharmacological Sciences 140 (2019) 171e177 175cells; however, no statistically signiﬁcant difference was observed
as vehicle-treated cells (Fig. 5B). FEN caused a concentration-
dependent increase in red spots in the cells and signiﬁcant at
106 M FEN (Fig. 5C). Similar results were obtained with the case
of DAMGO (data not shown).Fig. 5. Internalization of m-opioid receptors (MORs) induced by several opioids in HEK293 c
treated with the indicated opioids or a vehicle up to 180 min and were observed at the indic
and calculated as spot counts/cell (%). (A) Representative images at the indicated time point
treatment with each opioid. (C) Time course of internalized Halotag-MOR after treatment w
means ± S.E.M. (n ¼ 5e23). *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 versus
*p < 0.05 and **p < 0.01 versus vehicle. Scale bar ¼ 20 mm.4. Discussion
Activation of MOR by several opioids involves two downstream
pathways: one leads to mainly analgesic effects through a G protein-
mediated signaling pathway and the other may cause AEs through aells stably expressing Halotag-MOR. HEK293 cells stably expressing Halotag-MOR were
ated time points. To quantify internalization levels, red spots in the cells were counted
s in opioid-treated cells. (B) Time courses describing Halotag-MOR internalization after
ith various concentrations of fentanyl (FEN; 108 to 106 M). All data are presented as
vehicle. All data are presented as means ± S.E.M. for 5e23 independent experiments.
S. Manabe et al. / Journal of Pharmacological Sciences 140 (2019) 171e177176b-arrestin-mediated signaling pathway.3,11,12 Here, we evaluated the
induction of these pathways by opioids including HDM using several
experimental approaches. We found HDM to be biased toward the G
protein-mediated signaling pathway. EC50 values measured by cAMP
activity were FEN  HDM < MRP  OXY, indicating that HDM has
higher analgesic potency next to FEN. Internalization of MOR by
activation of the b-arrestin-mediated signaling pathway only
occurred in the case of FEN, suggesting that HDM could be a biased
agonist with a higher potency than MRP or OXY.
HDM, produced in 1924, has been used worldwide, but in Japan,
it was approved for clinical use only in 2017.15 Molecular charac-
terization of HDM using in vitro systems has not been documented.
However, Gharagozlou and colleagues have measured some prop-
erties of HDM in cells expressing mouse m, d, and k opioid receptors
to compare its effects with other opioids.18e20 They showed
the rank order cAMP inhibition potencies by MOR activation
was HDM > FEN > MRP.18 Our results are different:
FEN  HDM >MRP  OXY, which could be due to the inter-species
difference between OR clones, and/or cells expressing ORs (Chinese
hamster ovary [CHO] cells in theirs and HEK293 cells in ours).
In the present study, we determined MOR activities with the
CellKey™ system to measure GPCR-mediated whole cell activ-
ity.21,22 The CellKey™ assay can detect changes in cellular shape
and volume using cellular dielectric spectroscopy, an emergent
technology that measures whole-cell responses in a label-free
format.25 In our assay, the results of CellKey™ as well as cAMP
assay seemed to be similar, suggesting that both assays mainly
detected G protein-mediated signals. An earlier report demon-
strated that results from cAMP and CellKey™ assay in CHO cells
expressing dopamine D2S receptors had well correlated with D2S
agonist proﬁles.25 Further, we previously showed MOR-mediated
signaling by opioids and oxytocin with cAMP and CellKey™ assay
almost identical.21 These results suggest that data with the Cell-
Key™ and cAMP assay are representative of G protein-mediated
signaling, at least in the case of MOR.
We compared the potency and efﬁcacy of each opioid with four
types of cells expressing MOR with the CellKey™ assay. Our results
showed that the Emax and EC50 ratio of several opioids differed
slightly but not signiﬁcant among cell types. Previous experiments
with different tag-expressed d opioid receptors demonstrated that
there were no signiﬁcant differences between cell types.26 Our
results with cells in different tag-added MOR were not so different,
indicating that data obtained with the cells can be compared even
across the different measurement methods used in this study.
Internalization is a process through b-arrestin activation fol-
lowed by binding of the receptors and b-arrestin.3,11,27 For inter-
nalization assay, we used two different methods, ﬁrst to conﬁrm
that GFP-MOR upon activation internalized from cell surface to the
cytosol, and then to quantitatively measure Halotag-MOR inter-
nalized into cells. Cells expressing Halotag-MOR can be stained
with several types of “Halotag ligands” including for multicolor
ﬂuorescence imaging or detecting red spots at low pH in case of the
pH sensor-Halotag ligand.24 With the former method, GFP-MOR
internalized were observed from just beneath the membrane,
however, it might be difﬁcult to count numbers of GFP-MOR
objectively. With the latter method, Halotag-MOR pre-stained
with the pH-sensor ligand can be measured by counting red spots,
however, we may count internalized MOR only in the acidic
endoplasmic reticulum.24 With these two methods, nonetheless,
we showed that FEN and DAMGO caused robust internalization.
Accumulating evidence indicates that agonists for MOR that
activate only the G protein-signaling pathway are likely to cause
less AEs.3,11,28e30 We previously reported that another opioid
methadone is a b-arrestin-biased MOR agonist by comparing the
above two signaling pathway proﬁles.31 We also reported that FENbut not MRP, if treated repeatedly, caused the rapid development of
tolerance resulting in antihyperalgesic effects in a murine neuro-
pathic pain model,32 probably due to FEN-induced activation of b-
arrestin-mediated pathways. Taking our previous and present re-
sults into account, HDM would be classiﬁed as a G protein-biased
signaling agonist.
TRV130 has been reported to exhibit G protein-mediated
signaling over b-arrestin-mediated signaling and showed signiﬁ-
cantly attenuated AEs while maintaining its analgesic potency.29
Further, a synthetic analgesic SR-17018 activated G protein-
mediated but not b-arrestin-mediated signaling in vitro and
caused analgesic effects with less AEs in vivo.11 A recent review
regarding the discovery of novel opioids indicated that biased G
protein-mediated drugs are attractive candidates as MOR agonists
with lower AEs.30
In the clinic, the order of analgesic potency determined
by opioid conversion ratio is assumed to be
FEN < HDM < OXY MRP.33 Our results are slightly different, with
the order of potency being FEN  HDM < MRP < OXY. Intravenous
or intramuscular administration potency, however, has been re-
ported as FEN < HDM < MRP < OXY, which is well corelated with
ours.34,35 In clinical use, a single opioid affects many signaling
cascades that modulate analgesic potency (e.g. OXY also affects k-
OR36), and such situation should also be considered.
According to the Emax values, the efﬁcacy rates of MOR activa-
tion was FEN  OXY  MRP  HDM except in the CellKey™ assay
using GFP-MOR cells in vitro in our system. However, within
maximal clinical concentration levels for each opioid, HDM is
actually not aweak agonist. Themaximum plasma concentration of
each opioid (Cmax) is as follows: FEN, 6.84  109 M (100 mg/h
transdermal)37; OXY 2.60 107 M (40 mg in an immediate release
capsule)38; MRP 7.75  108 M (30 mg in an immediate release
tablet)39 and HDM 2.93  108 M (8 mg in an immediate release
tablet).40 Within these concentrations, the efﬁcacy of maximal
response of HDM is second to FEN (Figs. 2 and 3). In terms of Emax
below maximal clinical concentrations and EC50, HDM is indicated
as a biased agonist with a potent analgesic effect.
A meta-analysis study for comparison of clinical effects of HDM
and MRP conducted in 201141 showed that HDM had some ad-
vantages over MRP regarding analgesia. Further, side effects in
patients with renal failure or during acute analgesia titration were
lower with HDM than with MRP.41 However, this was based on
limited evidence and authors pointed out the need for further
conﬁrmation. A recent meta-analysis on opioid switching datawith
MRP, OXY, FEN, and HDM indicated that data of opioid switching
among them has little scientiﬁc basis and that further research-
based investigation is needed.33 In this context, further basic and
clinical studies regarding the properties of FEN, MRP, OXY, and
HDM are required.
In conclusion, we demonstrated that HDM has biased analgesic
properties. Comparison of MOR activities induced by several opi-
oids in the study showed that HDM could be a useful analgesic that
has a higher analgesic potency next to FEN and activates the b-
arrestin-mediated signaling pathway to a lesser extent.
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